Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative ¹⁸F-FDG PET/CT analysis.

ABSTRACT:

Background

Metastatic melanoma patients can have durable responses to systemic therapy and even long-term survival. However, a large subgroup of patients does not benefit. Tumour metabolic alterations may well be involved in the efficacy of both targeted and immunotherapy. Knowledge on in vivo tumour glucose uptake and its heterogeneity in metastatic melanoma may aid in upfront patient selection for novel (concomitant) metabolically targeted therapies. The aim of this retrospective study was to provide insight into quantitative ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) parameters and corresponding intra- and inter-patient heterogeneity in tumour ¹⁸F-FDG uptake among metastatic melanoma patients. Consecu

SUBMITTER: de Heer EC 

PROVIDER: S-EPMC6246760 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature